Gyan Bhanot
Affiliations: | Graduate School - New Brunswick | Rutgers University, New Brunswick, New Brunswick, NJ, United States |
Area:
General Biophysics, Bioinformatics Biology, OncologyGoogle:
"Gyan Bhanot"Mean distance: (not calculated yet)
Children
Sign in to add traineeErhan Bilal | grad student | 2010 | Rutgers, New Brunswick |
Aatish Bhatia | grad student | 2013 | Rutgers, New Brunswick |
Kshitij Wagh | grad student | 2013 | Rutgers, New Brunswick |
BETA: Related publications
See more...
Publications
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
Panda A, Yadav A, Yeerna H, et al. (2020) Tissue- and development-stage-specific mRNA and heterogeneous CNV signatures of human ribosomal proteins in normal and cancer samples. Nucleic Acids Research |
Santana LM, Ganesan S, Bhanot G. (2019) A Quasi Birth-and-Death Model For Tumor Recurrence. Journal of Theoretical Biology |
Singh A, Bhanot G, Khiabanian H. (2019) TuBA: Tunable biclustering algorithm reveals clinically relevant tumor transcriptional profiles in breast cancer. Gigascience. 8 |
Panda A, Stein MN, Riedlinger G, et al. (2019) Role for immune checkpoint blockade in BRCA2-mutant prostate cancer. Journal of Clinical Oncology. 37: 59-59 |
Ganesan S, Panda A, Bhanot G. (2019) Abstract B076: Pan-cancer analysis to identify which cancers may benefit most from LAG-3 blockade Cancer Immunology Research. 7 |
Smith CC, Beckermann KE, Bortone DS, et al. (2018) Endogenous retroviral signatures predict immunotherapy response in clear cell renal cell carcinoma. The Journal of Clinical Investigation |
Panda A, de Cubas AA, Stein M, et al. (2018) Endogenous retrovirus expression is associated with response to immune checkpoint blockade in clear cell renal cell carcinoma. Jci Insight. 3 |
Panda A, De Cubas A, Beckermann K, et al. (2018) Expression of endogenous retroviruses and response to immune checkpoint therapy in renal cell cancer. Journal of Clinical Oncology. 36: 104-104 |
Bjørklund SS, Panda A, Kumar S, et al. (2017) Widespread alternative exon usage in clinically distinct subtypes of Invasive Ductal Carcinoma. Scientific Reports. 7: 5568 |
Ganesan S, Bhanot G, Mehnert JM, et al. (2017) Mutation burden as a biomarker of response to immune checkpoint therapy in nine solid cancers. Journal of Clinical Oncology. 35: 35-35 |